Showing 1011-1020 of 1635 results for "".
- Nicox’s Partner Fera Pharmaceuticals to Investigate Naproxcinod as Potential COVID-19 Adjuvant Treatmenthttps://modernod.com/news/nicoxs-partner-fera-pharmaceuticals-to-investigate-naproxcinod-as-potential-covid-19-adjuvant-treatment/2478649/Nicox and Fera Pharmaceuticals announced that Fera will evaluate naproxcinod as a potential adjuvant treatment for patients with COVID-19 infection. Subject to successful completion of the ongoing manufacturing of naproxcinod test material, Fera plans to init
- Oyster Point Pharma Submits a Phase 2 Clinical Trial Protocol to Evaluate OC-01 Nasal Spray for Neurotrophic Keratitis (NK)https://modernod.com/news/oyster-point-pharma-submits-a-phase-2-clinical-trial-protocol-to-evaluate-oc-01-nasal-spray-for-neurotrophic-keratitis-nk/2478616/Oyster Point Pharma announced it has submitted to the FDA a protocol to initiate a clinical study in adult patients with neurotrophic keratitis (NK). The submission was made to Oyster Point’s investigational new drug (IND) for OC-01 (varenicline) nasal spray in dry eye disea
- Oyster Point Pharma Announces Clinical Data Presentations on OC-01 Nasal Spray for Dry Eye Disease at AAO Virtualhttps://modernod.com/news/oyster-point-pharma-announces-clinical-data-presentations-on-oc-01-nasal-spray-for-dry-eye-disease-at-aao-virtual/2478548/Oyster Point Pharma announced new data from its phase 2 IMPERIAL clinical trial evaluating OC-01 (varenicline) nasal spray in the treatment of the signs and symptoms of dry eye disease in adults at the AAO 2020 Virtual Annual Meeting, being held on November 13-15. A single administration o
- Nanoscope Therapeutics Announces Presentation at the 2020 AAOhttps://modernod.com/news/nanoscope-therapeutics-announces-presentation-at-the-2020-aao/2478545/Nanoscope Therapeutics, which is developing ocular gene therapy based on its proprietary ambient light activatable MCO Optogenetic Technology Platform, announced that an oral presentation at the Late Breaking Developments session of Retina Subspecialty Day will be made during the American Academy
- Llama ‘Nanobodies’ May Yield COVID-19 Treatment, Pitt Scientists Sayhttps://modernod.com/news/llama-nanobodies-may-yield-covid-19-treatment-pitt-scientists-say/2478500/Could Wally the llama hold the key to COVID-19? The immune system of the black-coated animal, who lives on a farm in Massachusetts, was coaxed into producing “nanobodies” — smaller cousins of antibodies — that neutralized the coronavirus in laboratory experiments, University of Pitt
- OD-OS Presents Navilas Laser System Pro 577s Navigated Retinal Laserhttps://modernod.com/news/od-os-presents-navilas-pro-as-an-affordable-entry-to-the-digital-ecosystem-of-navigated-laser/2478358/At the first virtual Euretina Congress, OD-OS presented the the Navilas Laser System 577s Pro for navigated retinal laser therapy. The Navilas Laser System 577s Pro supports precise and fast treatments of common retinal diseases, according to a company news release. It comes with the core trackin
- Saliva COVID-19 Test as Good as, Perhaps Beats, Nasal Swab: Studyhttps://modernod.com/news/saliva-covid-19-test-as-good-as-perhaps-beats-nasal-swab-study/2478248/A COVID-19 saliva test protocol developed by researchers at Yale University appeared to perform at least as well as nasal swabs in a study of hospital patients, a finding that may help encourage more frequent use of self-collected samples, according to a Medscape
- LumiThera Receives $1.5 Million Grant From National Eye Institute to Support Trial for Treating Diabetic Retinopathy and Macular Edemahttps://modernod.com/news/lumithera-receives-1-5-million-grant-from-national-eye-institute-to-support-trial-for-treating-diabetic-retinopathy-and-macular-edema/2478242/LumiThera announced it is a recipient of a small business innovative research (SBIR) phase 2 grant from the National Institute of Health (NIH) and the division of the National Eye Institute (NEI). The grant supports a prospective, randomized, multicenter human clinical trial in U.S. subjects diag
- Nanodropper Awarded a Phase 2 SBIR Contract With US Air Forcehttps://modernod.com/news/nanodropper-awarded-a-phase-2-sbir-contract-with-us-air-force/2478191/Nanodropper, the maker of an eyedrop bottle adaptor that reduces eyedrop size, has been named the recipient of a phase 2 Small Business Innovation Research (SBIR) contract with the United States Air Force. The Nanodropper adaptor was inspired by a 2017 ProPublica article detailing just how
- Omeros Reports Recovery and Survival of All Patients in Study Evaluating Narsoplimab for Treatment of COVID-19https://modernod.com/news/omeros-reports-recovery-and-survival-of-all-patients-in-study-evaluating-narsoplimab-for-treatment-of-covid-19/2478141/Omeros, maker of Omidria (phenylephrine and ketorolac intraocular solution 1%/0.3%) for use during cataract surgery to prevent miosis and reduce postoperative pain, reported the results of a compassionate-use study evaluating narso